Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.35 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.35 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.35 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.34 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA7 | P43166 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585836 | 0.98 | TSHR (0.38) | KMT2ATSHRCA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL2581502 | 0.88 | ALDH1A1 (0.40) | TSHRESR1KDM4ELMNACYP3A4 | |
| SCHEMBL2582297 | 0.86 | ALDH1A1 (0.41) | TSHRESR1KDM4ELMNACYP3A4 | |
| SCHEMBL23581909 | 0.82 | ESR1 (0.48) | TSHRESR1KDM4EMAPTLMNA | |
| SCHEMBL3043749 | 0.81 | TSHR (0.37) | KMT2ATSHRCA12CA1CA2 | |
| SCHEMBL27463224 | 0.81 | TSHR (0.37) | KMT2ATSHRCA12CA1CA2 | |
| SCHEMBL9805766 | 0.80 | CHRM3 (0.46) | TSHRCA12CA1CA2CA7 | |
| Iodide SCHEMBL28802571 | 0.78 | CHRM3 (0.45) | TSHRKDM4ELMNAGAA | |
| SCHEMBL17674060 | 0.76 | NPC1 (0.36) | TSHRKDM4EMAPTLMNAHPGD | |
| SCHEMBL28454809 | 0.75 | RAB9A (0.33) | KMT2ATSHRCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108553-A1 | Combination Therapy with Non-Selective COX Inhibitors to Prevent COX-Related Gastric Injuries | CORTRIA CORPORATION (US) | 2012-05-03 | — | — | US | claimed |
| US-20110269724-A1 | Combination Therapy with Non-Selective COX Inhibitors to Prevent COX-Related Gastric Injuries | CORTRIA CORPORATION (US) | 2011-11-03 | — | — | US | claimed |
| EP-1147086-B9 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | PHARMENA SP Z O O (PL) | 2010-09-22 | — | — | EP | claimed |
| EP-2203055-A1 | 1-METHYL NICOTINAMIDE AND DERIVATIVES FOR TREATMENT OF GASTRIC INJURY | Cortria Corporation (US) | 2010-07-07 | — | — | EP | claimed |
| US-20090118225-A1 | 1-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury | CORTRIA CORPORATION (US) | 2009-05-07 | — | — | US | claimed |
| WO-2009042440-A1 | 1-METHYL NICOTINAMIDE AND DERIVATIVES FOR TREATMENT OF GASTRIC INJURY | CORTRIA CORPORATION (US) | 2009-04-02 | — | — | WO | claimed |
| EP-2026651-A2 | COMBINATION THERAPY WITH NON-SELECTIVE COX INHIBITORS TO PREVENT COX-RELATED GASTRIC INJURIES | PHARMENA NORTH AMERICA INC. (CA) | 2009-02-25 | — | — | EP | claimed |
| EP-1919466-A2 | FORMULATIONS FOR TREATMENT OF LIPOPROTEIN ABNORMALITIES COMPRISING A STATIN AND A METHYLNICOTINAMIDE DERIVATIVE | PHARMENA NORTH AMERICA INC. (CA) | 2008-05-14 | — | — | EP | claimed |
| US-20070259861-A1 | Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries | PHARMENA NORTH AMERICA INC. (CA) | 2007-11-08 | — | — | US | claimed |
| WO-2007103540-A2 | COMBINATION THERAPY WITH NON-SELECTIVE COX INHIBITORS TO PREVENT COX-RELATED GASTRIC INJURIES | PHARMENA NORTH AMERICA INC. (CA) | 2007-09-13 | — | — | WO | claimed |
| WO-2007074406-A2 | FORMULATIONS FOR TREATMENT OF LIPOPROTEIN ABNORMALITIES COMPRISING A STATIN A STATIN AND A METHYLNICOTINAMIDE DERIVATIVE | PHARMENA NORTH AMERICA INC. (CA) | 2007-07-05 | — | — | WO | claimed |
| US-20070021379-A1 | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | PHARMENA NORTH AMERICA INC. (CA) | 2007-01-25 | — | — | US | claimed |
| EP-1147086-B1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2005-03-30 | — | — | EP | claimed |
| EP-1147086-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | Technical University of Lodz (PL) | 2001-10-24 | — | — | EP | claimed |
| WO-2000040559-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2000-07-13 | — | — | WO | claimed |
| US-8481570-B2 | 1-methylnicotinaide derivatives and formulations of treatment of lipoprotein abnormalities | CORTRIA CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120245115-A1 | 1-Methylnicotinaide Derivatives and Formulations of Treatment of Lipoprotein Abnormalities | CORTRIA CORPORATION (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2007103540-A2 | COMBINATION THERAPY WITH NON-SELECTIVE COX INHIBITORS TO PREVENT COX-RELATED GASTRIC INJURIES | PHARMENA NORTH AMERICA INC. (CA) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007074406-A2 | FORMULATIONS FOR TREATMENT OF LIPOPROTEIN ABNORMALITIES COMPRISING A STATIN A STATIN AND A METHYLNICOTINAMIDE DERIVATIVE | PHARMENA NORTH AMERICA INC. (CA) | 2007-07-05 | — | — | WO | disclosed |
| US-20070021379-A1 | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | PHARMENA NORTH AMERICA INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259861-A1 | Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries | PTGS1, PTGS2, PTGES2 | CA2 437/4885ESR1 3757/4885ESR2 2466/4885 |
| US-20070021379-A1 | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | HMGCR, NAMPT, NNMT | CA2 4820/4885ESR1 4651/4885ESR2 4341/4885 |
| US-20110269724-A1 | Combination Therapy with Non-Selective COX Inhibitors to Prevent COX-Related Gastric Injuries | PTGS1, PTGS2, PTGES2 | CA2 437/4885ESR1 3757/4885ESR2 2466/4885 |
| US-20090118225-A1 | 1-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury | NNMT, NAMPT, NNT | CA2 3163/4885ESR1 4576/4885ESR2 4652/4885 |
| US-20120108553-A1 | Combination Therapy with Non-Selective COX Inhibitors to Prevent COX-Related Gastric Injuries | PTGS1, PTGS2, PTGES2 | CA2 437/4885ESR1 3757/4885ESR2 2466/4885 |
| US-20120245115-A1 | 1-Methylnicotinaide Derivatives and Formulations of Treatment of Lipoprotein Abnormalities | HMGCR, NNMT, NAMPT | CA2 4799/4885ESR1 4430/4885ESR2 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.